Amgen’s sNDA for expanded labeling of Kyprolis cancer drug granted priority review
The FDA will review Kyprolis in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy, based on findings from the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.